



A novel thymidylate synthase from the *Vibrionales*, *Alteromonadales*, *Aeromonadales*, and *Pasteurellales* (VAAP) clade with altered nucleotide and folate binding sites

Alonso A. Lopez-Zavala^{1,2}, Eduardo Guevara-Hernandez¹, Luz H. Vazquez-Lujan¹, Arturo Sanchez-Paz³, Karina D. Garcia-Orozco¹, Carmen A. Contreras-Vergara⁴, Gamaliel Lopez-Leal⁵, Aldo A. Arvizu-Flores², Adrian Ochoa-Leyva⁵ and Rogerio R. Sotelo-Mundo¹

¹ Biomolecular Structure Laboratory, Centro de Investigación en Alimentación y Desarrollo, A.C., Hermosillo, Sonora, Mexico

² Departamento de Ciencias Químico Biológicas, Universidad de Sonora, Hermosillo, Sonora, Mexico

³ Laboratorio de Referencia, Análisis y Diagnóstico en Sanidad Acuicola, Centro de Investigaciones Biológicas del Noroeste, Hermosillo, Sonora, Mexico

⁴ Laboratorio de Genética de Plantas, Centro de Investigación en Alimentación y Desarrollo, A.C., Hermosillo, Sonora, Mexico

⁵ Departamento de Microbiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico

ABSTRACT

Thymidylate synthase (TS, E.C. 2.1.1.45) is a crucial enzyme for *de novo* deoxythymidine monophosphate (dTMP) biosynthesis. The gene for this enzyme is *thyA*, which encodes the folate-dependent TS that converts deoxyuridine monophosphate group (dUMP) into (dTMP) using the cofactor 5,10-methylenetetrahydrofolate (mTHF) as a carbon donor. We identified the *thyA* gene in the genome of the *Vibrio parahaemolyticus* strain FIM-S1708+ that is innocuous to humans but pathogenic to crustaceans. Surprisingly, we found changes in the residues that bind the substrate dUMP and mTHF, previously postulated as invariant among all TSs known (*Finer-Moore, Santi & Stroud, 2003*). Interestingly, those amino acid changes were also found in a clade of microorganisms that contains *Vibrionales*, *Alteromonadales*, *Aeromonadales*, and *Pasteurellales* (VAAP) from the *Gammaproteobacteria* class. In this work, we studied the biochemical properties of recombinant TS from *V. parahaemolyticus* FIM-S1708+ (VpTS) to address the natural changes in the TS amino acid sequence of the VAAP clade. Interestingly, the K_m for dUMP was $27.3 \pm 4.3 \mu\text{M}$, about one-fold larger compared to other TSs. The K_m for mTHF was $96.3 \pm 18 \mu\text{M}$, about three- to five-fold larger compared to other species, suggesting also loss of affinity. Thus, the catalytic efficiency was between one or two orders of magnitude smaller for both substrates. We used trimethoprim, a common antibiotic that targets both TS and DHFR for inhibition studies. The IC_{50} values obtained were high compared to other results in the literature. Nonetheless, this molecule could be a lead for the design antibiotics towards pathogens from the VAAP clade. Overall, the experimental results also suggest that in the VAAP clade the nucleotide salvage pathway is important and should be investigated, since the *de novo* dTMP synthesis appears to be compromised by a less efficient thymidylate synthase.

Submitted 1 March 2018

Accepted 23 May 2018

Published 15 June 2018

Corresponding author
Rogerio R. Sotelo-Mundo,
rrs@ciad.mx

Academic editor
Vladimir Uversky

Additional Information and
Declarations can be found on
page 13

DOI 10.7717/peerj.5023

© Copyright
2018 Lopez-Zavala et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Aquaculture, Fisheries and Fish Science, Biochemistry, Marine Biology, Microbiology, Drugs and Devices

Keywords *Vibrio parahaemolyticus*, Trimethoprim, Gammaproteobacteria, Alteromonadales, Enzyme, Aeromonadales, *Pasteurellales*, Thymidylate synthase

INTRODUCTION

Pathogens comprise a highly complex and diverse community of organisms that include viruses, bacteria, fungi, protozoans, parasitic arthropods, mollusks, worms, and few chordates (Bergh *et al.*, 1989; Suttle, 2005; Kristensen *et al.*, 2010). Because of the constant adverse conditions imposed by their hosts to escape infection, pathogens rapidly evolve sophisticated strategies to evade or subvert the host immune response after its establishment (Aguileta *et al.*, 2009).

Bacterial infections from *Vibrio* are still a critical problem in human health (Colwell, 1996), and also to aquatic organisms (Holmström *et al.*, 2003; Wang, Li & Lin, 2008).

Bacteria from the genus *Vibrio* are part of the natural microflora of wild and cultured shrimp species (Gomez-Gil *et al.*, 1998; Esiobu & Yamazaki, 2003; Liu *et al.*, 2011; Cornejo-Granados *et al.*, 2017), although some species, as *V. harveyi*, *V. alginolyticus*, *V. anguillarum*, *V. vulnificus*, *V. splendidus* and *V. parahaemolyticus* have usually been associated with diseases in shrimp and shellfish (Lavilla-Pitogo, 1995; Sung *et al.*, 2001; Hsu & Chen, 2007; Kumar *et al.*, 2014; Cornejo-Granados *et al.*, 2017).

By the end of 2009, the emergence of a new bacterial pathogen affected shrimp aquaculture in China and later spread to Vietnam, Malaysia, and Thailand (Leaño & Mohan, 2012; De Schryver, Defoirdt & Sorgeloos, 2014). Eventually, the disease reached the Western Hemisphere and emerged in Mexico in early 2013 (Nunan *et al.*, 2014). Several studies have demonstrated that the etiological agent of this disease, initially referred as Early Mortality Syndrome or EMS, and more recently named Acute Hepatopancreatic Necrosis Disease or AHPND (Lightner *et al.*, 2012) were specific strains of *V. parahaemolyticus* that do not contain neither the human pathogenic markers *tdh* (thermostable direct hemolysin) nor *trh* (tdh-related hemolysin) (Tran *et al.*, 2013; Joshi *et al.*, 2014; Soto-Rodriguez *et al.*, 2015). In fact, the AHPND-causing strains of *V. parahaemolyticus* harbor a 70 kbp plasmid, which encodes two toxins, *ToxA* and *ToxB*, homologs of the *Photobacterium* insect-related (Pir) toxins *PirA* and *PirB* (Lee *et al.*, 2015). Currently, there are no active treatments available against this toxigenic *Vibrio* strains, and there is a need for of antibacterial strategies. As with any other living organism, during the bacterial division cycle, the pools of nucleotides must be maintained at relatively constant concentrations, and nucleotide synthesis is greatly stimulated (Lane & Fan, 2015). Therefore, this pathway could be targeted with antibacterial compounds.

Thymidylate synthase (EC 2.1.1.45, TS) catalyzes the reductive methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP) and dihydrofolate, assisted by the co-factor 5,10-methylenetetrahydrofolate (mTHF) (Carreras & Santi, 1995). This reaction is the final step in the only *de novo* synthetic pathway to thymidylate, so it is essential for DNA replication. *thyA* corresponds to the folate-dependent TS found in *E. coli* (Belfort *et al.*, 1983), invertebrates, vertebrates

and humans. Recently, a novel flavin-dependent TS was described as *thyX*. (Mylykallio *et al.*, 2002), which also has been postulated as an antibacterial target (Choi, Karunaratne & Kohen, 2016).

Folate-dependent TS is an excellent drug target for cancer cells, and there are examples of drugs in clinical use (Jarmula, 2010). TS is also a good target for antibacterial infectious diseases (Ferrari, Costi & Wade, 2003). The folate-dependent TS (*thyA*) has been thoroughly studied in bacteria to a structural detail where the function of every active-site amino acid residue has been determined (Finer-Moore, Santi & Stroud, 2003). Nonetheless, with the advent of massive genome sequencing, changes in bacterial *thyA*-conserved residues have been identified. For example, changes in charged residues close to the active site have been found in *Wigglesworthia glossinidia* TS (Garg *et al.*, 2015). The importance of electrostatics in the TS active site was demonstrated by successive mutagenesis of *E. coli* TS towards the charged residues in *W. glossinidia*, observing important changes in the kinetic parameters of the mutants (Garg *et al.*, 2015). Importantly, *V. parahaemolyticus* strain FIM-S11708+ TS (Gomez-Jimenez *et al.*, 2014) has a change to glycine in one of the four arginines that coordinate the nucleotide-phosphate group.

Indeed, little is known regarding the biochemical properties, functionality and metabolic role of TS on Gammaproteobacteria or Vibrionales whatsoever that are pathogenic to humans or marine organisms. Therefore, this study aimed to investigate the biochemical properties of the TS from a *V. parahaemolyticus* toxigenic strain (VpTS). Comparison of the Michaelis–Menten kinetic parameters, enzyme inhibition with a known antibacterial such as trimethoprim and molecular modeling provides insight into the importance of the *de novo* dTMP biosynthesis into the VAAP clade.

MATERIALS AND METHODS

Genome used and thymidylate synthase orthologous genes

We used the thymidylate synthase *Vibrio parahaemolyticus* (GenBank WP_100088861.1) found in the FIM-S11708+ strain genome deposited as GenBank JPLV00000000.1 (Gomez-Jimenez *et al.*, 2014) as a seed to identify the homologous TS, using blast searches with an *E*-value cutoff of 1.0×10^{-15} against the proteomes encoded in 38 genomes belonging to the gamma-proteobacteria class (File S1). All proteins that shown an alignment $\leq 70\%$ of their length were kept for further analysis. We collected these genomes for two reasons: First, to get a better perspective of the variation of the TS across the Gammaproteobacteria (primarily focused on the active site) and second, these genomes have been used in phylogenomic analyses of that bacterial class (Williams *et al.*, 2010).

Phylogeny among the thymidylate synthase

To conduct a Maximum Likelihood (ML) phylogeny, we created a protein Multiple Sequence Alignment (MSA) using MUSCLE with 50 iterations (Edgar, 2004). We ran the ML phylogeny specifying the LG+G+I model, as determined by ProtTest3 (Darriba *et al.*, 2011) and using non-parametric bootstrap analysis (100 replicates) to establish the support for the clades. The phylogenetic tree was colored and edited using FigTree v1.4.3 (<http://tree.bio.ed.ac.uk/software/figtree/>).

VpTS expression and purification

VpTS was expressed in *Escherichia coli* using a codon-optimized synthetic gene cloned into the T7-promoter expression vector pJexpress414 which contains the ampicillin resistance gene (DNA2.0). We used the amino acid sequence of *Vibrio parahaemolyticus* thymidylate synthase (GenBank [WP_100088861.1](#)) including in the N-terminus a 10 His-tag and the cutting site for the PreScission Protease (GE Healthcare, Little Chalfont, UK). The total theoretical mass would be 35,944 Da and the tag could be removed upon treatment with the protease.

The *E. coli* BL21(DE3)-SI strain was used to express VpTS. To facilitate yield of soluble protein we used a plasmid containing the chaperones groES-groEL-Tig (TAKARA plasmid PG-Tf2). For this, the bacteria were transformed first with plasmid pPG-Tf2 with chloramphenicol selection at 20 µg/mL, and later with the pJexpress414-VpTS plasmid using chloramphenicol and ampicillin at 100 µg/mL. Both antibiotics were used in all further procedures.

A 5 mL of a starter culture of transformed bacteria was incubated overnight and used to inoculate 1 L of LB broth without NaCl. The bacteria were incubated in an orbital shaker at 250 rpm at 37 °C. When an optical density of 0.4 at 600 nm was obtained, chaperone expression was induced by addition of tetracycline to a final concentration of 9 ng/mL. When optical density reached 0.6 units ($\lambda = 600$ nm), the T7-promoter was induced with IPTG and NaCl to a final concentration of 0.1 mM and 0.3 M respectively. Cell growth was continued for 24 h at 25 °C. The bacterial pellet was obtained by centrifugation at $7,500 \times g$ at 4 °C, and the biomass was lysed by sonication in 20 mM potassium phosphate buffer pH 7.5, 5 mM dithiothreitol (DTT), 0.5 mM phenyl methyl sulfonyl fluoride (PMSF), and 5 mM benzamidine. The bacterial lysate was clarified at $25,000 \times g$ for 20 min at 4 °C.

For metal affinity chromatography, a 5 mL Ni-His Trap column (GE Healthcare) was equilibrated with 20 mM phosphate buffer pH 7.5, 0.5 M NaCl (buffer A) in an Äkta Prime chromatographer (GE Healthcare) at 1 mL/min. The clarified lysate was loaded into the column and washed with at least five volumes of buffer A until the absorbance at 280 nm returned to baseline. Elution was done with a linear gradient of buffer A and buffer A plus 500 mM imidazole. Fractions of 3 mL were collected. Purification was followed by 12% SDS-PAGE using pre-casted TGX stain-free gels (BioRad) and images were recorded on a GelDoc Easy Imaging system (BioRad). The TGX stain-free detection system has a sensitivity comparable to silver staining ([Gilda & Gomes, 2013](#)).

To further purify VpTS and confirm the oligomeric state, size exclusion chromatography was used using a Superdex 75 10/300 column in an Äkta Pure chromatographer (GE Healthcare) at 1 mL/min with Tris HCl 20 mM pH 7.5 and NaCl 100 mM as running buffer. Molecular weight (MW) standards were aprotinin (6.5 kDa), ribonuclease A (13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin (44 kDa), conalbumin (75 kDa) and Blue Dextran (2,000 kDa) to determine the column void volume. VpTS native molecular weight was calculated from linear regression of a K_{av} vs. log MW plot, using the formula

$$K_{av} = (V_t - V_o) / (V_f - V_o)$$

where V_t is the total column volume, V_o is the void column and V_f is the volume where the sample or a molecular weight standard is eluted. Fractions were analyzed by 12% SDS-PAGE as mentioned above. Purified protein was quantitated using the bicinchoninic acid method (BCA kit; Pierce, Waltham, MA, USA).

VpTS kinetics and IC₅₀ inhibition

TS kinetics were determined using a spectrophotometric assay following the formation of dihydrofolate at 340 nm ($\epsilon_{340\text{ nm}} = 6,400\text{ M}^{-1}\text{ cm}^{-1}$) in a CARY-50 (Varian) UV-vis spectrophotometer as previously described ([Arvizu-Flores et al., 2009](#)). The reaction buffer contained 50 mM Tris-HCl pH 7.5, 5 mM DTT, 1 mM EDTA, 25 mM MgCl₂. The substrates were mTHF (Schircks Laboratories, Jona, Switzerland) and dUMP (Sigma-Aldrich, St. Louis, MO, USA). The assay was done in a final volume of 1 mL at 30 °C. The reaction was started by addition of 0.3 μM of recombinant VpTS, and the initial rates were determined by recording the absorbance increase at 340 nm, changing the substrate concentration for mTHF (0–300 μM) and dUMP (0–150 μM). Experimental data were obtained in triplicate and fitted to the Michaelis–Menten equation by a non-linear regression analysis using the GraFit software (Erithacus Software).

Steady-state IC₅₀ inhibition was determined with trimethoprim (TRIM, Sigma-Aldrich, St. Louis, MO, USA) as an antifolate in standard activity conditions ([Arvizu-Flores et al., 2009](#)) with saturating substrate concentrations (mTHF 300 μM and dUMP 150 μM) by triplicate. Data were adjusted to a dose–response model using non-linear fit with the GraFit software.

Structure modeling

The VpTS structural model was built using Protein Homology/analogY Recognition Engine V Phyre2.0 server ([Kelley et al., 2015](#)). The best model was selected by the highest sequence identity, alignment coverage and model confidence factor within the closed conformation structures. The most similar bacterial structure in the dUMP-bound closed conformation, was *E. coli* TS (32% of sequence identity; PDB 1AXW) as the reference structure. The structural analysis was performed in CCP4MG V7.0 program ([McNicholas et al., 2011](#))

RESULTS

Expression and purification of VpTS

VpTS was co-expressed with the set of chaperones groES-groEL-Tig in *E. coli* strain BL21-SI, observing that the protein was best expressed at 24 h post induction. This was observed in the SDS-PAGE follow-up of expression, where VpTS migrated to an approximate mass of 35 kDa ([Fig. 1A](#)). This value is within the range of the theoretical molecular weight of 35,944 Da taking into account the 10-His tag. Besides VpTS, there was a highly co-expressed protein at 60 kDa corresponding to the GroEL chaperone molecular weight ([Fig. 1A](#)).

VpTS was purified by IMAC chromatography purification as seen in the SDS-PAGE of the chromatography fractions ([Fig. 1B](#)). VpTS eluted at an imidazole concentration of 375 mM, as observed VpTS in the asterisk lane of [Fig. 1B](#). The yield of VpTS after IMAC chromatography was 40 mg of protein per liter.




Figure 1 Recombinant expression and purification of VpTS. SDS-PAGE was done in BioRad TGX 12% Stain Free precast gels. 20 mL of protein sample were treated with the same volume of 2X SDS-Sample buffer, heated 5 min at 95 °C and loaded per lane. (A) SDS-PAGE of bacterial lysates from expression in LB media. Lanes represent 0, 2, 4, 5 and 24 h after induction with IPTG. (B) Protein purification follow-up using nickel His-tag affinity chromatography. Lane L represents a sample of the bacterial lysate loaded into the column. Lane nb comes from non-bound proteins. Lane ub corresponds to unspecific bound proteins eluted with 10 mM imidazole and the asterisk (*) lane corresponds to VpTS eluted with 375 mM imidazole. (C) Size Exclusion Chromatography. The chromatogram recorded at 280 nm is included showing the volume where VpTS eluted (10.35 mL). As inset, the SDS-PAGE of selected fractions corresponding to the peak are included. M stands for the molecular weight markers, L for the sample loaded and 12–17 corresponding to the fractions around the peak at 10.35 mL. Second inset, the K_{av} vs. log MW plot is shown, where the VpTS native molecular weight mass was interpolated to 70 kDa.

Full-size [DOI: 10.7717/peerj.5023/fig-1](https://doi.org/10.7717/peerj.5023/fig-1)

We also included an extra purification step using size-exclusion chromatography, to confirm the native dimeric TS quaternary structure. A molecular weight of 70 kDa was interpolated from the analysis of the after mentioned calculation (Fig. 1C). The gel filtration purified protein had the same specific TS activity, therefore for enzymatic assays we used VpTS purified by IMAC chromatography only. This has been found also for varicella




Figure 2 Michaelis-Menten kinetics for VpTS using dUMP as substrate. Initial velocities were measured by triplicate and kinetic parameters were obtained by non-linear fitting with robust weighting as implemented in the GraFit software. Standard error bars are included.

Full-size [DOI: 10.7717/peerj.5023/fig-2](https://doi.org/10.7717/peerj.5023/fig-2)

zoster TS, confirming that IMAC was sufficient for VpTS kinetic studies (Hew *et al.*, 2015). Instead of Coomassie Blue or silver staining, TGX stain-free 12% polyacrylamide gels (BioRad) were used during all the purification steps, since they provide a good method to validate protein purity (Gilda & Gomes, 2013; Rivero-Gutiérrez *et al.*, 2014).

Enzymatic and inhibition assay

Kinetic parameters for dUMP were $27.3 \pm 4.3 \mu\text{M}$ for K_m , 0.3 s^{-1} for k_{cat} , and $0.01 \mu\text{M}^{-1} \text{ s}^{-1}$ for kinetic efficiency (Fig. 2). For mTHF, the values were $K_m 96.3 \pm 18 \mu\text{M}$, $k_{cat} 0.3 \text{ s}^{-1}$, and a kinetic efficiency of $0.0031 \mu\text{M}^{-1} \text{ s}^{-1}$ (Fig. 3). These values are higher than those reported for other TS in previous works (Table 1), clearly indicating that a loss of affinity occurs for both substrate and cofactor compared to prokaryotic and eukaryotic TSs (Greene *et al.*, 1994; Spencer, Villafranca & Appleman, 1997; Fox *et al.*, 1999; Sergeeva *et al.*, 2003; Pozzi *et al.*, 2012). Inhibition of VpTS was studied using TRIM, which is a broad range inhibitor of bacterial TS and dihydrofolate reductase (DHFR). Inhibition data were adjusted to a non-linear dose-response model obtaining an IC_{50} value of $106 \mu\text{M}$, with a standard error of $11.36 \mu\text{M}$ (Fig. 4).




Figure 3 Michaelis-Menten kinetics for VpTS using mTHF as substrate. Initial velocities were measured by triplicate and kinetic parameters were obtained by non-linear fitting with robust weighting as implemented in the GraFit software. Standard error bars are included.
 [Full-size](#)
[DOI: 10.7717/peerj.5023/fig-3](https://doi.org/10.7717/peerj.5023/fig-3)

Table 1 Comparison of kinetics parameters for TS from different organisms. Standard deviation values are included where available.

Organism	k_{cat} (s^{-1})	K_m dUMP (μM)	K_m mTHF (μM)	k_{cat}/K_m dUMP ($\mu M^{-1} s^{-1}$)	k_{cat}/K_m mTHF ($\mu M^{-1} s^{-1}$)	
<i>V. parahaemolyticus</i>	0.3	27.3 $\pm$ 4.3	96.3 $\pm$ 18	0.01	0.003	This work
<i>L. vannamei</i>	4.1	2.1	13.5	1.95	0.030	<i>Arvizu-Flores et al. (2009)</i>
WSSV	2.8	1.2	13.4	2.33	0.209	<i>Arvizu-Flores et al. (2009)</i>
<i>L. casei</i>	5.1	2.6	20	1.96	0.255	<i>Kawase et al. (2000)</i>
<i>E. coli</i>	1.9	1.2	11	1.58	0.173	<i>Spencer, Villafranca & Appleman (1997)</i>
<i>L. lactis</i>	11	7.2	19	1.53	0.579	<i>Greene et al. (1994)</i>
<i>E. faecalis</i>	4.3	7.0	20	0.65	0.215	<i>Pozzi et al. (2012)</i>
<i>B. subtilis</i>	20	3.4	11.2	5.88	1.786	<i>Fox et al. (1999)</i>
Human	0.21	2.7 $\pm$ 0.33	10.1 $\pm$ 0.7			<i>Sergeeva et al. (2003)</i>

Phylogenetic analysis of thymidylate synthases among the Gammaproteobacteria

To get a more compressive view of the molecular evolution of the TS among the gammaproteobacteria, we constructed an ML-phylogeny using 38 genomes ([File S1](#)), which represent the main orders of the Gammaproteobacteria. We have aligned selected TS amino




Figure 4 TRIM concentration for 50% inhibition (IC_{50}) of the VpTS. The depicted curve describes the inhibition of TS activity, where y-axis corresponds to the initial velocity (V_0) of TS, and the x-axis to the logarithmic TRIM concentration. Standard error bars are included.

Full-size [DOI: 10.7717/peerj.5023/fig-4](https://doi.org/10.7717/peerj.5023/fig-4)

acid sequences and highlighted in yellow the active site residues (File S2). The first thing we noticed is that two main clades were formed and the small clade (orange) corresponds to the VAAP: Vibrionales, Alteromonadales, Pasteurellales and Oceanospirales (Fig. 5). Interestingly, the TS of *Shewanella amazonensis*, *Shewanella denitrificans*, *Shewanella baltica*, *Shewanella* sp. MR-4, *Shewanella putrefaciens* and *Pseudoalteromonas tunicate*, do not reflect a history of the species according to the species tree of these genomes previously reported (Williams et al., 2010). These results suggest that these TS and other genes could be acquired by horizontal gene transfer in these phylogenetic clades.

Moreover, from the amino acid sequence alignment (File S2), we confirmed that all residues that form the canonical TS active site are invariant, except for the TSs in the VAAP clade (Fig. 5, orange rectangle). One of them was a conservative change of lysine to arginine at position 50 in VpTS (Table 2). This residue is important for folate binding as it makes an ionic contact between the mTHF γ -glutamate and its mutation reduces folate affinity (Arvizu-Flores et al., 2008). The other change is more dramatic, a glycine for an arginine at position 141' in VpTS (Fig. 5, orange rectangle). This change leaves three arginines to coordinate the dUMP phosphate group and possibly reduces nucleotide affinity (Table 2). Other authors have also found that position Arg179' (equivalent to VpTS Gly141') was relatively permissive to mutations (Kawase et al., 2000).




Figure 5 Phylogeny of TS for selected Gammaproteobacterias. Maximum likelihood phylogeny of Thymidylate synthase based on protein sequences alignment. The labels are colored corresponding to the different gammaproteobacteria orders: brown, Enterobacteriales; blue, Vibrionales; green, Pasteurellales; purple, Alteromonadales; light blue (cyan), Oceanospirales; navy blue, Pseudomonadales and Xanthomonadales in yellow. The numbers next to the nodes correspond to the bootstrap values for some of the main clades, plus signs show nodes with 70 or higher bootstrap support. Asterisks denote nodes with less than 70 bootstrap support. The orange rectangle contains all the sequences that contain a glycine in position 141 (G141) vs. the consensus arginine (R). The sequences used on this analysis are located in [File S2](#).

Full-size  DOI: 10.7717/peerj.5023/fig-5

Table 2 Function of invariant residues in TS. Selected residues with critical function for TS catalytic activity are listed for *V. parahaemolyticus*, *E. coli*, *L. casei* and human sequences. Based on [Finer-Moore, Santi & Stroud \(2003\)](#).

<i>V. para.</i>	<i>E. coli</i>	<i>L. casei</i>	Human	Function
Cys160	Cys146	Cys198	Cys195	Catalytic residue for nuclephilic attack to dUMP
Asn191	Asn178	Asn229	Asn226	Substrate specificity towards dUMP base
His221	His207	His259	His256	Hydrogen bonding with dUMP ribose hydroxyl
Tyr223	Tyr209	Tyr261	Tyr258	<i>idem</i>
Trp82	Trp80	Trp82	Trp109	Positioning of folate
Arg22	Arg21	Arg23	Arg50	dUMP phosphate binding
Arg140'	Arg126'	Arg178'	Arg175'	<i>idem</i>
Gly141'	Arg127'	Arg179'	Arg176'	<i>idem</i>
Arg180	Arg166	Arg218	Arg215	<i>idem</i>
Arg50	Lys48	Lys50	Lys77	Ionic interaction with γ -glutamate from mTHF




Figure 6 Prediction of the active site of VpTS. The theoretical model of VpTS (represented in light blue ribbons) was superimposed to the crystallographic structure of *E. coli* TS bound to dUMP (represented in light grey ribbons; PDB 1AWX). The nucleotide is represented as cylinders and colored by atom type (carbon in green, nitrogen in blue, oxygen in red, phosphorous in magenta). The catalytic cysteine and phosphate-binding arginines are included. Two invariant arginine residues VpArg180/Ec166 and VpArg140'/Ec126' are presented. Residues from the opposite monomer have a prime (') in their numbering. Critical sequence changes are VpGly141'/EcArg127, and an arrow is indicating the position of the alpha-carbon for VpGly141'. Hydrogen bonds are shown as dotted lines based on the crystallographic structure.

Full-size [DOI: 10.7717/peerj.5023/fig-6](https://doi.org/10.7717/peerj.5023/fig-6)

Molecular modeling of the dUMP binding site in VpTS

The sequence of VpTS was modeled with Phyre2 to predict the three-dimensional structure of the enzyme. TS has a well-described conformational change from an open active site when unbound or dUMP is present. A closed conformation occurs when the nucleotide and a folate analog are bound (*Finer-Moore, Santi & Stroud, 2003*). We modeled a dUMP-bound complex by superposing the Phyre2-VpTS model with an *E. coli* TS structure (PDB 1AXW) with a 100% confidence level and 99% alignment coverage. We confirmed that the nucleotide phosphate was coordinated by three invariant arginine residues in VpTS: Arg22, Arg 140' and Arg180 (Fig. 6). For clarity, Arg22 was not included the figure. As mentioned above, VpTS lacks the fourth arginine residue (Ec Arg127'; Lc Arg179'; hArg176'; see Table 2) that is important to stabilize the phosphate group by two hydrogen bonds. The presence of glycine in this position (Gly141') is recurrent in the VAAP clade (File S2).

DISCUSSION

The kinetic results for the VpTS are consistent with loss of one arginine residue involved in dUMP binding. Loss of affinity for the VpTS nucleotide substrate led to a reduction

in catalytic efficiency compared to other TSs (Table 1). Proteins that participate directly and indirectly in the generation of nucleotides for DNA replication are highly conserved in sequence as well as in their structure (Cui et al., 2013). TS is an homodimer where each active site is comprised of residues from both monomers, although without any cooperativity (Sapienza, Falk & Lee, 2015). These differences are usually exploited in drug development for proliferative disease treatment where the pathogen and the host share the same enzyme (Carreras & Santi, 1995; De Clercq, 2002). Sequence analysis showed that VpTS has important amino acid changes concerning the consensus TSs known to this date (Table 2 and File S2).

A key change is the loss of one of the four arginine residues that coordinate the dUMP phosphate group by the presence of Gly141' where most of TSs have an arginine residue. Site-directed mutagenesis studies in *L. casei* TS have demonstrated that changes in this position are allowed (Kawase et al., 2000), meaning that the enzyme still retains enzymatic activity.

To our knowledge, this is the first report of an organism where naturally one of the four nucleotide-binding arginines was substituted by another residue. Likewise, a change of Arg179' for Ala, Thr, Lys or Glu, led to higher values of K_m in all directed-site mutants (Santi et al., 1990). In *E. coli*, Arg166 (Arg180 in VpTS) is fundamental for the thiolate formation beside nucleotide binding (Sotelo-Mundo et al., 2006). There are two other arginines that also coordinate the nucleotide phosphate, the Arg126' and Arg 127' in EcTS, which correspond to Arg140' and Gly141' in *V. parahaemolyticus*, respectively. Arg126' has been studied structurally since a conservative mutation impairs catalysis and the structure (Strop et al., 1997).

We concluded that the increase in K_m for dUMP in VpTS may reflecting a loss in affinity for the nucleotide due to less favorable interactions with the dUMP phosphate. TS has an ordered kinetic mechanism, where dUMP is the first substrate bound (Spencer, Villafranca & Appleman, 1997), therefore the K_m for mTHF is also affected and k_{cat}/K_m too.

An additional change in the active site vicinity occurs at VpTS Met161, where other species have a His or Lys that makes hydrogen bonds with the uridine ring. Loss of an additional hydrogen bond by the loss of the imidazole group at position 161 could be an additional factor in a reduced nucleotide affinity. In previous works, it was shown that the changes in EcHis147, affect significantly the TS catalytic efficiency (Dev et al., 1989; LaPat-Polasko, Maley & Maley, 1990).

The conservative change at position 50 may have a steric effect over folate binding. In the T4 phage TS, the Lys48Arg mutation increased its K_m value for mTHF by two orders of magnitude respect to the wild-type enzyme. This change in size and not in charge may contribute to the increase in mTHF K_m for mTHF compared to other species (Table 1).

TRIM inhibition of VpTS

Some treatments against proliferative, microbial, inflammatory and parasitic diseases have been focused on folate metabolism inhibition (Gonen & Assaraf, 2012). TRIM is an antifolate with structural differences respect to methotrexate, which increase their specificity for the bacterial DHFR (Navarrete et al., 2013). In this work, the inhibitory

capacity by TRIM for VpTS was evaluated. The IC_{50} value was 106 μ M, whereas values for bacterial DHRF are usually very low, such as 0.001 μ M for *Haemophilus influenzae* and 0.01 μ M for *E. coli* (Wax, 2008). Although TRIM is not a potent inhibitor of TS, due to its commercial availability, it is possible to improve its affinity to TS by rational drug design that would allow inhibition values comparable to the specific compounds for TS.

CONCLUSION

In conclusion, we experimentally evaluated the biochemical properties of VpTS found in the VAAP clade that had changes in key residues for substrate binding. These changes do not imply the loss of function from site-directed mutagenesis studies done in other TSs. Nonetheless, considering that the active site of TS is invariant from phages to human, a further detail into the alternative pathway for dTMP biosynthesis such as nucleotide salvage by thymidine kinase is worth investigating. Also, the evolutionary history of the VAAP clade should deserve attention, as part of the microbiota of marine organisms and as some important pathogens such as *Vibrio* sp.

ACKNOWLEDGEMENTS

We thank Bruno Zavala-Contreras M.Sc. for size-exclusion chromatography experiments.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by CONACYT Mexico' National Council on Science and Technology (CB-2014-237963; CB-2013-223279) and a graduate scholarship to L.H. Vazquez-Lujan and a postdoctoral fellowship to G. López-Leal. Funding was also received from UNAM-CIC-CIAD-2017 academic exchange program, and from CIAD' CTAOA and Coordinación de Investigación. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
CONACYT Mexico' National Council on Science and Technology: CB-2014-237963, CB-2013-223279.
UNAM-CIC-CIAD-2017 academic exchange program.
CIAD's CTAOA and Coordinación de Investigación.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Alonso A. Lopez-Zavala conceived and designed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.

- Eduardo Guevara-Hernandez performed the experiments, analyzed the data, prepared figures and/or tables, approved the final draft.
- Luz H. Vazquez-Lujan conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, approved the final draft.
- Arturo Sanchez-Paz authored or reviewed drafts of the paper, approved the final draft.
- Karina D. Garcia-Orozco performed the experiments, prepared figures and/or tables, approved the final draft.
- Carmen A. Contreras-Vergara and Gamaliel Lopez-Leal analyzed the data, approved the final draft.
- Aldo A. Arvizu-Flores conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, approved the final draft.
- Adrian Ochoa-Leyva analyzed the data, contributed reagents/materials/analysis tools, approved the final draft.
- Rogerio R. Sotelo-Mundo conceived and designed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.

Data Availability

The following information was supplied regarding data availability:

The sequences are available in GenBank: [WP_100088861.1](#), [JPLV00000000.1](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.5023#supplemental-information>.

REFERENCES

- Aguileta G, Refregier G, Yockteng R, Fournier E, Giraud T. 2009.** Rapidly evolving genes in pathogens: methods for detecting positive selection and examples among fungi, bacteria, viruses and protists. *Infection, Genetics and Evolution* **9**:656–670 DOI [10.1016/j.meegid.2009.03.010](#).
- Arvizu-Flores AA, Aispuro-Hernandez E, Garcia-Orozco KD, Varela-Romero A, Valenzuela-Soto E, Velazquez-Contreras EF, Rojo-Domínguez A, Yepiz-Plascencia G, Maley F, Sotelo-Mundo RR. 2009.** Functional identity of the active sites of crustacean and viral thymidylate synthases. *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology* **150**:406–413 DOI [10.1016/j.cbpc.2009.06.008](#).
- Arvizu-Flores AA, Sugich-Miranda R, Arreola R, Garcia-Orozco KD, Velazquez-Contreras EF, Montfort WR, Maley F, Sotelo-Mundo RR. 2008.** Role of an invariant lysine residue in folate binding on Escherichia coli thymidylate synthase: calorimetric and crystallographic analysis of the K48Q mutant. *The International Journal of Biochemistry & Cell Biology* **40**:2206–2217 DOI [10.1016/j.biocel.2008.02.025](#).

- Belfort M, Maley G, Pedersen-Lane J, Maley F. 1983. Primary structure of the *Escherichia coli* *thyA* gene and its thymidylate synthase product. *Proceedings of the National Academy of Sciences of the United States of America* DOI 10.1073/pnas.80.16.4914.
- Bergh Ø, Børsheim KY, Bratbak G, Haldal M. 1989. High abundance of viruses found in aquatic environments. *Nature* 340:467–468 DOI 10.1038/340467a0.
- Carreras CW, Santi DV. 1995. The catalytic mechanism and structure of thymidylate synthase. *Annual Review of Biochemistry* 64:721–762 DOI 10.1146/annurev.bi.64.070195.003445.
- Choi M, Karunaratne K, Kohen A. 2016. Flavin-dependent thymidylate synthase as a new antibiotic target. *Molecules* DOI 10.3390/molecules21050654.
- Colwell RR. 1996. Global climate and infectious disease: the cholera paradigm. *Science* 274:2025–2031 DOI 10.1126/science.274.5295.2025.
- Cornejo-Granados F, Lopez-Zavala AA, Gallardo-Becerra L, Mendoza-Vargas A, Sánchez F, Vichido R, Briebe LG, Viana MT, Sotelo-Mundo RR, Ochoa-Leyva A. 2017. Microbiome of Pacific Whiteleg shrimp reveals differential bacterial community composition between Wild, Aquacultured and AHPND/EMS outbreak conditions. *Scientific Reports* 7:Article 11783 DOI 10.1038/s41598-017-11805-w.
- Cui Q, Shin WS, Luo Y, Tian J, Cui H, Yin D. 2013. Thymidylate kinase: an old topic brings new perspectives. *Current Medicinal Chemistry* 20:1286–1305 DOI 10.2174/0929867311320100006.
- Darriba D, Taboada GL, Doallo R, Posada D. 2011. ProtTest 3: fast selection of best-fit models of protein evolution. *Bioinformatics* 27:1164–1165 DOI 10.1093/bioinformatics/btr088.
- De Clercq E. 2002. Strategies in the design of antiviral drugs. *Nature Reviews Drug Discovery* 1:13–25 DOI 10.1038/nrd703.
- De Schryver P, Defoirdt T, Sorgeloos P. 2014. Early mortality syndrome outbreaks: a microbial management issue in shrimp farming? *PLOS Pathogens* 10:e1003919 DOI 10.1371/journal.ppat.1003919.
- Dev IK, Yates BB, Atashi J, Dallas WS. 1989. Catalytic role of histidine 147 in *Escherichia coli* thymidylate synthase. *Journal of Biological Chemistry* 264:19132–19137.
- Edgar RC. 2004. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. *BMC Bioinformatics* 5:113 DOI 10.1186/1471-2105-5-113.
- Esiobu N, Yamazaki K. 2003. Analysis of bacteria associated with the gut of healthy wild penaeid shrimps: a step towards effective probiotics in aquaculture. *Journal of Aquaculture in the Tropics* 8:275–286.
- Ferrari S, Costi PM, Wade RC. 2003. Inhibitor specificity via protein dynamics: insights from the design of antibacterial agents targeted against thymidylate synthase. *Chemistry & Biology* 10:1183–1193 DOI 10.1016/j.
- Finer-Moore JS, Santi DV, Stroud RM. 2003. Lessons and conclusions from dissecting the mechanism of a bisubstrate enzyme: thymidylate synthase mutagenesis, function, and structure. *Biochemistry* 42:248–256 DOI 10.1021/bi020599a.

- Fox KM, Maley F, Garibian A, Changchien L-M, Van Roey P. 1999.** Crystal structure of thymidylate synthase A from *Bacillus subtilis*. *Protein Science* **8**:538–544 DOI [10.1110/ps.8.3.538](https://doi.org/10.1110/ps.8.3.538).
- Garg D, Skouloubris S, Briffotiaux J, Myllykallio H, Wade RC. 2015.** Conservation and role of electrostatics in thymidylate synthase. *Scientific Reports* **5**:17356 DOI [10.1038/srep17356](https://doi.org/10.1038/srep17356).
- Gilda JE, Gomes A.V. 2013.** Stain-Free total protein staining is a superior loading control to β -actin for Western blots. *Analytical Biochemistry* **440**:186–188 DOI [10.1016/J.AB.2013.05.027](https://doi.org/10.1016/J.AB.2013.05.027).
- Gomez-Gil B, Tron-Mayen L, Roque A, Turnbull JF, Inglis V, Guerra-Flores AL. 1998.** Species of *Vibrio* isolated from hepatopancreas, haemolymph and digestive tract of a population of healthy juvenile *Penaeus vannamei*. *Aquaculture* **163**:1–9 DOI [10.1016/S0044-8486\(98\)00162-8](https://doi.org/10.1016/S0044-8486(98)00162-8).
- Gomez-Jimenez S, Noriega-Orozco L, Sotelo-Mundo RR, Cantu-Robles VA, Cobian-Guemes AG, Cota-Verdugo RG, Gamez-Alejo LA, Del Pozo-Yauner L, Guevara-Hernandez E, Garcia-Orozco KD. 2014.** High-quality draft genomes of two *Vibrio parahaemolyticus* strains aid in understanding acute hepatopancreatic necrosis disease of cultured shrimps in Mexico. *Genome Announcements* **2**:e00800–14 DOI [10.1128/genomeA.00800-14](https://doi.org/10.1128/genomeA.00800-14).
- Gonen N, Assaraf YG. 2012.** Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. *Drug Resistance Updates* **15**:183–210 DOI [10.1016/j.drug.2012.07.002](https://doi.org/10.1016/j.drug.2012.07.002).
- Greene PJ, Yu P, Zhao J, Schiffer CA, Santi D. 1994.** Expression, purification, and characterization of thymidylate synthase from *Lactococcus lactis*. *Protein Science* **3**:1114–1116 DOI [10.1002/pro.5560030715](https://doi.org/10.1002/pro.5560030715).
- Hew K, Dahlroth SL, Veerappan S, Pan LX, Cornvik T, Nordlund P. 2015.** Structure of the varicella zoster virus thymidylate synthase establishes functional and structural similarities as the human enzyme and potentiates itself as a target of brivudine. *PLOS ONE* DOI [10.1371/journal.pone.0143947](https://doi.org/10.1371/journal.pone.0143947).
- Holmström K, Gräslund S, Wahlström A, Pongshompoo S, Bengtsson B, Kautsky N. 2003.** Antibiotic use in shrimp farming and implications for environmental impacts and human health. *International Journal of Food Science & Technology* **38**:255–266 DOI [10.1046/j.1365-2621.2003.00671.x](https://doi.org/10.1046/j.1365-2621.2003.00671.x).
- Hsu S-W, Chen J-C. 2007.** The immune response of white shrimp *Penaeus vannamei* and its susceptibility to *Vibrio alginolyticus* under sulfide stress. *Aquaculture* **271**:61–69 DOI [10.1016/j.aquaculture.2007.05.028](https://doi.org/10.1016/j.aquaculture.2007.05.028).
- Jarmula A. 2010.** Antifolate inhibitors of thymidylate synthase as anticancer drugs. *Mini-Reviews in Medicinal Chemistry* **10**:1211–1222 DOI [10.2174/13895575110091211](https://doi.org/10.2174/13895575110091211).
- Joshi J, Srisala J, Truong VH, Chen I-T, Nuangsaeng B, Suthienkul O, Lo CF, Flegel TW, Sritunyalucksana K, Thitamadee S. 2014.** Variation in *Vibrio parahaemolyticus* isolates from a single Thai shrimp farm experiencing an outbreak

- of acute hepatopancreatic necrosis disease (AHPND). *Aquaculture* **428**:297–302 DOI [10.1016/j.aquaculture.2014.03.030](https://doi.org/10.1016/j.aquaculture.2014.03.030).
- Kawase S, Cho S-W, Rozelle J, Stroud RM, Finer-Moore J, Santi D.V. 2000. Replacement set mutagenesis of the four phosphate-binding arginine residues of thymidylate synthase. *Protein Engineering* **13**:557–563 DOI [10.1093/protein/13.8.557](https://doi.org/10.1093/protein/13.8.557).
- Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. 2015. The Phyre2 web portal for protein modeling, prediction and analysis. *Nature Protocols* **10**:845–858 DOI [10.1038/nprot.2015.053](https://doi.org/10.1038/nprot.2015.053).
- Kristensen DM, Mushegian AR, Dolja VV, Koonin E.V. 2010. New dimensions of the virus world discovered through metagenomics. *Trends in Microbiology* **18**:11–19 DOI [10.1016/j.tim.2009.11.003](https://doi.org/10.1016/j.tim.2009.11.003).
- Kumar BK, Deekshit VK, Raj JRM, Rai P, Shivanagowda BM, Karunasagar I, Karunasagar I. 2014. Diversity of *Vibrio parahaemolyticus* associated with disease outbreak among cultured *Litopenaeus vannamei* (Pacific white shrimp) in India. *Aquaculture* **433**:247–251 DOI [10.1016/j.aquaculture.2014.06.016](https://doi.org/10.1016/j.aquaculture.2014.06.016).
- Lane AN, Fan TW-M. 2015. Regulation of mammalian nucleotide metabolism and biosynthesis. *Nucleic Acids Research* **43**:2466–2485 DOI [10.1093/nar/gkv047](https://doi.org/10.1093/nar/gkv047).
- LaPat-Polasko L, Maley GF, Maley F. 1990. Properties of bacteriophage T4 thymidylate synthase following mutagenic changes in the active site and folate binding region. *Biochemistry* **29**:9561–9572 DOI [10.1021/bi00493a010](https://doi.org/10.1021/bi00493a010).
- Lavilla-Pitogo CR. 1995. Bacterial diseases of penaeid shrimps: an Asian view. Phuket: Fish Health Section, Asian Fisheries Society, 107–121.
- Leaño EM, Mohan C.V. 2012. Early mortality syndrome threatens Asia's shrimp farms. *Global Aquaculture Advocate* **2012**:38–39.
- Lee C-T, Chen I-T, Yang Y-T, Ko T-P, Huang Y-T, Huang J-Y, Huang M-F, Lin S-J, Chen C-Y, Lin S-S. 2015. The opportunistic marine pathogen *Vibrio parahaemolyticus* becomes virulent by acquiring a plasmid that expresses a deadly toxin. *Proceedings of the National Academy of Sciences of the United States of America* **112**:10798–10803 DOI [10.1073/pnas.1503129112](https://doi.org/10.1073/pnas.1503129112).
- Lightner DV, Redman RM, Pantoja CR, Noble BL, Tran L. 2012. Early mortality syndrome affects shrimp in Asia. *Global Aquaculture Advocate* **15**:40.
- Liu H, Wang L, Liu M, Wang B, Jiang K, Ma S, Li Q. 2011. The intestinal microbial diversity in Chinese shrimp (*Fenneropenaeus chinensis*) as determined by PCR-DGGE and clone library analyses. *Aquaculture* **317**:32–36 DOI [10.1016/j.aquaculture.2011.04.008](https://doi.org/10.1016/j.aquaculture.2011.04.008).
- McNicholas S, Potterton E, Wilson KS, Noble MEM. 2011. Presenting your structures: the CCP 4 mg molecular-graphics software. *Acta Crystallographica Section D Biological Crystallography* **67**:386–394 DOI [10.1107/S0907444911007281](https://doi.org/10.1107/S0907444911007281).
- Myllykallio H, Lipowski G, Leduc D, Filee J, Forterre P, Liebl U. 2002. An alternative flavin-dependent mechanism for thymidylate synthesis. *Science* DOI [10.1126/science.1072113](https://doi.org/10.1126/science.1072113).

- Navarrete O, Van Daele J, Stove C, Lambert W, Storozhenko S, Van Der Straeten D. 2013. Isolation and characterisation of an antifolate insensitive (afi1) mutant of *Arabidopsis thaliana*. *Plant Biology* 15:37–44 DOI 10.1111/j.1438-8677.2012.00602.x.
- Nunan L, Lightner D, Pantoja C, Gomez-Jimenez S. 2014. Detection of acute hepatopancreatic necrosis disease (AHPND) in Mexico. *Diseases of Aquatic Organisms* 111:81–86 DOI 10.3354/dao02776.
- Pozzi C, Ferrari S, Cortesi D, Luciani R, Stroud RM, Catalano A, Costi MP, Mangani S. 2012. The structure of *Enterococcus faecalis* thymidylate synthase provides clues about folate bacterial metabolism. *Acta Crystallographica Section D: Biological Crystallography* 68:1232–1241 DOI 10.1107/S0907444912026236.
- Rivero-Gutiérrez B, Anzola A, Martínez-Augustín O, De Medina FS. 2014. Stain-free detection as loading control alternative to Ponceau and housekeeping protein immunodetection in Western blotting. *Analytical Biochemistry* 467:1–3 DOI 10.1016/j.ab.2014.08.027.
- Santi DV, Pinter K, Kealey J, Davisson VJ. 1990. Site-directed mutagenesis of arginine 179 of thymidylate synthase. A nonessential substrate-binding residue. *Journal of Biological Chemistry* 265:6770–6775.
- Sapienza PJ, Falk BT, Lee AL. 2015. Bacterial thymidylate synthase binds two molecules of substrate and cofactor without cooperativity. *Journal of the American Chemical Society* 137:14260–14263 DOI 10.1021/jacs.5b10128.
- Sergeeva OA, Khambatta HG, Cathers BE, Sergeeva MV. 2003. Kinetic properties of human thymidylate synthase, an anticancer drug target. *Biochemical and Biophysical Research Communications* DOI 10.1016/S0006-291X(03)01173-2.
- Sotelo-Mundo RR, Changchien L, Maley F, Montfort WR. 2006. Crystal structures of thymidylate synthase mutant R166Q: structural basis for the nearly complete loss of catalytic activity. *Journal of Biochemical and Molecular Toxicology* 20:88–92 DOI 10.1002/jbt.20122.
- Soto-Rodriguez SA, Gomez-Gil B, Lozano-Olvera R, Betancourt-Lozano M, Morales-Covarrubias MS. 2015. Field and experimental evidence of *Vibrio parahaemolyticus* as the causative agent of acute hepatopancreatic necrosis disease of cultured shrimp (*Litopenaeus vannamei*) in Northwestern Mexico. *Applied and Environmental Microbiology* 81:1689–1699 DOI 10.1128/AEM.03610-14.
- Spencer HT, Villafranca JE, Appleman JR. 1997. Kinetic scheme for thymidylate synthase from *Escherichia coli*: determination from measurements of ligand binding, primary and secondary isotope effects, and pre-steady-state catalysis. *Biochemistry* 36:4212–4222 DOI 10.1021/bi961794q.
- Strop P, Montfort WR, Changchien L, Maley F. 1997. Crystal structures of a marginally active thymidylate synthase mutant, Arg 126 → Glu. *Protein Science* 6:2504–2511 DOI 10.1002/pro.5560061203.
- Sung H-H, Hsu S-F, Chen C-K, Ting Y-Y, Chao W-L. 2001. Relationships between disease outbreak in cultured tiger shrimp (*Penaeus monodon*) and the composition

- of *Vibrio* communities in pond water and shrimp hepatopancreas during cultivation. *Aquaculture* **192**:101–110 DOI [10.1016/S0044-8486\(00\)00458-0](https://doi.org/10.1016/S0044-8486(00)00458-0).
- Suttle CA. 2005.** Viruses in the sea. *Nature* **437**:356–361 DOI [10.1038/nature04160](https://doi.org/10.1038/nature04160).
- Tran L, Nunan L, Redman RM, Mohny LL, Pantoja CR, Fitzsimmons K, Lightner D.V. 2013.** Determination of the infectious nature of the agent of acute hepatopancreatic necrosis syndrome affecting penaeid shrimp. *Diseases of Aquatic Organisms* **105**:45–55 DOI [10.3354/dao02621](https://doi.org/10.3354/dao02621).
- Wang Y-B, Li J-R, Lin J. 2008.** Probiotics in aquaculture: challenges and outlook. *Aquaculture* **281**:1–4 DOI [10.1016/j.aquaculture.2008.06.002](https://doi.org/10.1016/j.aquaculture.2008.06.002).
- Wax RG. 2008.** *Bacterial resistance to antimicrobials*. Boca Raton: CRC Press.
- Williams KP, Gillespie JJ, Sobral BWS, Nordberg EK, Snyder EE, Shallom JM, Dickerman AW. 2010.** Phylogeny of gammaproteobacteria. *Journal of Bacteriology* **192**:2305–2314 DOI [10.1128/JB.01480-09](https://doi.org/10.1128/JB.01480-09).